About: Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis
Creator	Afshari, Arash Allingstrup, Mikkel Møller, Ann Ravn, Frederikke Wetterslev, Jørn
source	PMC
abstract	PURPOSE: Antithrombin III (AT III) is an anticoagulant with anti-inflammatory properties. We assessed the benefits and harms of AT III in critically ill patients. METHODS: We searched from inception to 27 August 2015 in CENTRAL, MEDLINE, EMBASE, CAB, BIOSIS and CINAHL. We included randomized controlled trials (RCTs) irrespective of publication status, date of publication, blinding status, outcomes published or language. RESULTS: We included 30 RCTs with a total of 3933 participants. The majority of included trials were at high risk of bias. Combining all trials, regardless of bias, showed no statistically significant effect of AT III on mortality (RR 0.95, 95 % CI 0.88–1.03, I (2) = 0 %, fixed-effect model, 29 trials, 3882 participants). Among those with severe sepsis and disseminated intravascular coagulation (DIC), AT III showed no impact on mortality (RR 0.95, 95 % Cl 0.88–1.03, I (2) = 0 %, fixed-effect model, 12 trials, 2858 participants). We carried out multiple subgroup and sensitivity analyses to assess the benefits and harms of AT III and to examine the impact of risk of bias. AT III significantly increased bleeding events (RR 1.58, 95 % CI 1.35–1.84, I (2) = 0 %, fixed-effect model, 11 trials, 3019 participants). However, for all other outcome measures and analyses, the results did not reach statistical significance. CONCLUSIONS: There is insufficient evidence to support AT III substitution in any category of critically ill participants including those with sepsis and DIC. AT III did not show an impact on mortality, but increased the risk of bleeding. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00134-016-4225-7) contains supplementary material, which is available to authorized users.
has issue date	2016-02-09(xsd:dateTime)
bibo:doi	10.1007/s00134-016-4225-7
bibo:pmid	26862016
has license	no-cc
sha1sum (hex)	599d48a88ceb17a9fcd2debd2cc0fcc356812aa0
schema:url	https://doi.org/10.1007/s00134-016-4225-7
resource representing a document's title	Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis
has PubMed Central identifier	PMC7095103
has PubMed identifier	26862016
schema:publication	Intensive Care Med
resource representing a document's body	covid:599d48a88ceb17a9fcd2debd2cc0fcc356812aa0#body_text
is schema:about of	named entity 'critically ill' named entity 'patients' covid:arg/599d48a88ceb17a9fcd2debd2cc0fcc356812aa0 named entity 'III' named entity 'Purpose' named entity 'critically ill patients' named entity 'anticoagulant' named entity 'critically ill patients' named entity 'systematic review' named entity 'meta-analysis' named entity 'obstetric' named entity 'heparin' named entity 'TSA' named entity 'statistical significance' named entity 'fresh frozen plasma' named entity 'data management' named entity 'double-blinding' named entity 'albumin' named entity 'AT III' named entity 'Type 1 error' named entity 'sample size' named entity 'DIC' named entity 'fluid resuscitation' named entity 'heparin' named entity 'physiology' named entity 'coronary artery bypass graft' named entity 'statistically significant' named entity 'APTT' named entity 'TSA' named entity '1.03' named entity 'critically ill' named entity 'surgical intervention' named entity 'heterogeneity' named entity '1.1' named entity 'systematic reviews' named entity 'cellular receptor' named entity 'relative risk reduction' named entity 'non-significant' named entity 'heparin' named entity 'loading dose' named entity 'thrombosis' named entity 'confidence interval' named entity 'anticoagulant' named entity 'confidence interval' named entity 'follow-up' named entity 'chronic obstructive pulmonary disease' named entity 'infection' named entity 'statistical significance' named entity 'HIV' named entity 'Glasgow coma scale' named entity 'sepsis' named entity 'systematic review' named entity 'continuity correction' named entity 'chronic health' named entity 'sensitivity analysis' named entity 'meta-analyses' named entity 'respiratory failure' named entity 'randomization' named entity 'inflammatory' named entity '0.98' named entity 'TSA' named entity 'procoagulant' named entity '1.10' named entity 'crossover design' named entity 'RRR' named entity 'Heparin' named entity 'randomization' named entity 'RRR' named entity 'Belgium' named entity 'critical illness' named entity 'ICU' named entity 'DIC' named entity 'antithrombin' named entity 'heterogeneity' named entity 'MPI' named entity 'immune dysfunction' named entity 'electronic searches'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software